CCCC
C4 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.33
+0.76%Year over year
Reported trailing growth
- Revenue
- +2.3%
- EBITDA
- +6.4%
- EBIT
- +9.6%
- EPS
- +36.7%
- Free cash flow
- +2.5%
- Operating cash flow
- +2.9%
Forward estimates
Based on analyst estimates
- Revenue
- -40.8%
- EBITDA
- -23.6%
- EPS
- +4.8%
Three-year CAGR
- Revenue
- +5.0%
- EBITDA
- +0.4%
- EBIT
- +12.6%
- Net income
- +0.3%
- EPS
- +16.4%
- Free cash flow
- -52.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026